Valuation: PFIZER

Market Cap 140B 140B 122B 113B 104B 197B 13,354B 201B 1,351B 530B 6,558B 524B 512B 22,648B P/E 2026 *
12.4x
P/E 2027 * 12.9x
Enterprise Value 189B 189B 166B 153B 141B 267B 18,072B 272B 1,828B 717B 8,875B 709B 694B 30,650B EV / Sales 2026 *
3.06x
EV / Sales 2027 * 3.08x
Free-Float
59.06%
Yield 2026 *
7.05%
Yield 2027 * 7.12%
Manager TitleAgeSince
Chief Executive Officer 64 2018-12-31
Director of Finance/CFO 60 2022-05-01
Chief Tech/Sci/R&D Officer - 2006-12-31
Director TitleAgeSince
Director/Board Member 68 2007-08-31
Director/Board Member 62 2013-09-26
Chairman 64 2019-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.56%-1.52%+49.04%+171.88% 1,054B
+0.31%-0.60%+64.29%+62.31% 621B
-0.03%-2.65%+28.86%+85.64% 438B
-1.75%-0.33%+28.78%+23.58% 325B
+0.24%-0.42%+29.46%+47.26% 281B
-1.75%-10.57%+20.67%+22.07% 262B
+0.67%+1.03%-26.10%-37.96% 219B
-0.81%-1.63%+22.07%+58.33% 195B
+1.21%+1.38%+19.85%+71.29% 163B
Average -0.23%-1.70%+26.32%+56.05% 395.13B
Weighted average by Cap. -0.27%-1.69%+36.29%+84.00%

Financials

2026 *2027 *
Net sales 61.74B 61.74B 54.16B 50.16B 46.15B 87.29B 5,910B 88.99B 598B 234B 2,902B 232B 227B 10,022B 59.36B 59.36B 52.07B 48.22B 44.37B 83.93B 5,682B 85.56B 575B 225B 2,790B 223B 218B 9,636B
Net income 10.63B 10.63B 9.32B 8.63B 7.94B 15.02B 1,017B 15.32B 103B 40.36B 499B 39.91B 39.03B 1,725B 10.27B 10.27B 9.01B 8.34B 7.67B 14.52B 983B 14.8B 99.41B 38.99B 483B 38.56B 37.71B 1,667B
Net Debt 49.3B 49.3B 43.24B 40.05B 36.85B 69.7B 4,718B 71.05B 477B 187B 2,317B 185B 181B 8,002B 43.17B 43.17B 37.86B 35.07B 32.27B 61.03B 4,132B 62.22B 418B 164B 2,029B 162B 159B 7,007B
Logo PFIZER
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (47.4%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (26.2%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (24.5%); - other (1.9%). The United States accounts for 60.8% of net sales.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A